Breaking News Instant updates and real-time market news.

ILMN

Illumina

$332.15

-0.26 (-0.08%)

07:45
08/07/18
08/07
07:45
08/07/18
07:45

Illumina upgraded to Equal Weight on broadening support at Morgan Stanley

As previously reported, Morgan Stanley analyst Steve Beuchaw upgraded Illumina to Equal Weight from Underweight, admitting that his prior thesis overestimated the impact of new products such as NovaSeq on utilization of the legacy installed base and failed to value critical new markets. He now sees it as clear that broadening support for sequencing applications across faster-growing existing markets and into emerging markets de-risks the long-term outlook, Beuchaw tells investors. He raised his price target on Illumina shares to $320 from $210, stating that he sees a path to $40B in sales by 2040.

  • 08

    Aug

  • 27

    Aug

ILMN Illumina
$332.15

-0.26 (-0.08%)

07/31/18
SBSH
07/31/18
NO CHANGE
Target $345
SBSH
Buy
Illumina price target raised to $345 from $330 at Citi
Citi analyst Daniel Arias raised his price target for Illumina to $345 and keeps a Buy rating on the shares. Last night's Q2 represented the largest revenue beat since the early days of the HiSeq X launch in Q2 of 2014, Arias tells investors in a research note. The analyst expects the shares to trade up "nicely" on the earnings print.
07/31/18
ADAM
07/31/18
NO CHANGE
Target $340
ADAM
Buy
Illumina Q2 beat was 'massive' and broad-based, says Canaccord
Canaccord analyst Mark Massaro said Illumina delivered outstanding Q2 results with a broad-based beat. The analyst said the major beat and raised guidance keeps the stock as a must own for 2018. He now sees a clear path to over $4B in revenues by 2020. Massaro reiterated his Buy rating and raised his price target to $340 from $330 on Illumina shares.
07/31/18
DBAB
07/31/18
NO CHANGE
Target $330
DBAB
Buy
Illumina price target raised to $330 from $280 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Illumina to $330 saying the "strong beat" in Q2 on stronger NovaSeq demand supports his thesis. The analyst sees upside for estimates over the next 6-12 months and reiterates a Buy rating on the shares.
08/07/18
MSCO
08/07/18
UPGRADE
MSCO
Equal Weight
Illumina upgraded to Equal Weight from Underweight at Morgan Stanley

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.